Abstract
In the therapy of chronic and dangerous conditions like as cancer, heart disease, neurological illnesses, or retinal angiopathy, we frequently require most effective dosage schedule with adequate precision and sufficient therapeutic potential. Among these entities with the capacity to behave in a target-specific way are aptamers. Usually, they are produced by an iterative screening procedure named “Systemic Evolution of Ligands by Exponential Enrichment (SELEX)” which is used to complicate nucleic acid libraries. For several biological purposes, including targeted treatment, aptamers are potential and could be easily molded into desirable needs and also be tested in a manner that is not very extravagant or pricey. Chemical modification can be employed to enhance their pharmacological actions or prevent enzymatic degradation, hence guaranteeing their chemical integrity and bioavailability in a physiological setting. The recent advancements made in drug targeting and design with the use of aptamers are the main topic of this review. This review will highlight current developments and go over prospects and problems in the fields of aptamer-based targeted therapy, including aptamer therapeutics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
